Symptomatic AD treatment fails in first phase III.
Asher
A
Mullard
D000544:Alzheimer Disease / Q000188:drug therapy*; D001596:Benzylamines / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D005466:Fluorocarbons
D001596:Benzylamines; D007211:Indoles; C568612:(2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine; D005466:Fluorocarbons